24.22
+0.22(+0.92%)
Currency In USD
| Previous Close | 24 |
| Open | 24.48 |
| Day High | 24.6 |
| Day Low | 23.75 |
| 52-Week High | 130 |
| 52-Week Low | 6.76 |
| Volume | 936,349 |
| Average Volume | 1.51M |
| Market Cap | 212.31M |
| PE | 0.01 |
| EPS | 2,537 |
| Moving Average 50 Days | 34.82 |
| Moving Average 200 Days | 28.74 |
| Change | 0.22 |
If you invested $1000 in Tonix Pharmaceuticals Holding Corp. (TNXP) 10 years ago, it would be worth $0 as of October 06, 2025 at a share price of $24.22. Whereas If you bought $1000 worth of Tonix Pharmaceuticals Holding Corp. (TNXP) shares 5 years ago, it would be worth $0.05 as of October 06, 2025 at a share price of $24.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access
GlobeNewswire Inc.
Sep 30, 2025 12:30 PM GMT
Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fib
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
GlobeNewswire Inc.
Sep 29, 2025 11:00 AM GMT
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 granted Orphan Drug and Rare Pediatric Disease Designat
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
GlobeNewswire Inc.
Sep 18, 2025 12:00 PM GMT
Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL is FDA-approved for the treatment of fibromyalgia CH